Bowen Hanes & Co. Inc. Makes New $542,000 Investment in Bristol Myers Squibb Company $BMY

Bowen Hanes & Co. Inc. purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 10,045 shares of the biopharmaceutical company’s stock, valued at approximately $542,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC boosted its holdings in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC boosted its holdings in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,786 shares during the period. United Bank boosted its holdings in Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the period. Marshall Wace LLP purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $405,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Jefferies reiterated its Buy rating on Bristol Myers Squibb, which supports the stock’s valuation case and may be helping sentiment. Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
• Positive Sentiment: Bristol Myers said Opdivo received an EU label expansion for use with AVD in newly diagnosed advanced classical Hodgkin lymphoma, a commercial win that could lift future oncology revenue. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in kidney cancer, adding another pipeline-related catalyst. Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan…

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Finally, UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $54.89 on Thursday. The business’s fifty day moving average price is $58.15 and its 200 day moving average price is $56.45. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The stock has a market capitalization of $112.09 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period last year, the business posted $1.80 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.